I agree that this site is using cookies. You can find further informations here.
X
Berges, Alienor
28  results:
Search for persons X
?
1

Predicting the Long‐Term Effects of Therapeutic Neutralizat..:

Thorsted, Anders ; Zecchin, Chiara ; Berges, Alienor..
Clinical Pharmacology & Therapeutics.  , 2024
Link: https://doi.org/10.1002/..
 
?
2

Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Co..:

Yap, Timothy A. ; Krebs, Matthew G. ; Postel-Vinay, Sophie...
Clinical Cancer Research.  27 (2021)  19 - p. 5213-5224 , 2021
Link: https://doi.org/10.1158/..
 
?
3

Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage..:

Kim, Seung Tae ; Smith, Simon A. ; Mortimer, Peter...
Clinical Cancer Research.  27 (2021)  17 - p. 4700-4709 , 2021
Link: https://doi.org/10.1158/..
 
?
4

Concentration‐QT modelling in early clinical oncology setti..:

Cantet, Gael ; Berges, Alienor ; O'Sullivan, Rhianna...
British Journal of Clinical Pharmacology.  88 (2021)  3 - p. 1010-1019 , 2021
Link: https://doi.org/10.1111/..
 
?
5

Computer-assembled cross-species/cross-modalities two-pore ..:

Sepp, Armin ; Meno-Tetang, Guy ; Weber, Andrew...
Journal of Pharmacokinetics and Pharmacodynamics.  46 (2019)  4 - p. 339-359 , 2019
Link: https://doi.org/10.1007/..
 
?
6

Efficacy and Safety Exposure‐Response Analyses of Olaparib ..:

Zhou, Diansong ; Li, Jianguo ; Learoyd, Maria...
Clinical Pharmacology & Therapeutics.  105 (2019)  6 - p. 1492-1500 , 2019
Link: https://doi.org/10.1002/..
 
?
7

Time-to-Event Modeling of Left- or Right-Censored Toxicity ..:

Berges, Alienor ; Cerou, Marc ; Sahota, Tarjinder...
Toxicological Sciences.  165 (2018)  1 - p. 50-60 , 2018
Link: https://doi.org/10.1093/..
 
?
8

Bridging Olaparib Capsule and Tablet Formulations Using Pop..:

Zhou, Diansong ; Li, Jianguo ; Bui, Khanh...
Clinical Pharmacokinetics.  58 (2018)  5 - p. 615-625 , 2018
Link: https://doi.org/10.1007/..
 
?
9

Development of a physiologically based pharmacokinetic mode..:

Sepp, Armin ; Berges, Alienor ; Sanderson, Andrew.
Journal of Pharmacokinetics and Pharmacodynamics.  42 (2015)  2 - p. 97-109 , 2015
Link: https://doi.org/10.1007/..
 
?
10

Ozanezumab Dose Selection for Amyotrophic Lateral Sclerosis..:

Berges, Alienor ; Bullman, Jonathan ; Bates, Stewart...
PLOS ONE.  10 (2015)  2 - p. e0117355 , 2015
Link: https://doi.org/10.1371/..
 
?
11

Comparing probabilistic and descriptive analyses of time–do..:

Glatard, Anaïs ; Berges, Aliénor ; Sahota, Tarjinder...
Toxicology and Applied Pharmacology.  288 (2015)  2 - p. 240-248 , 2015
Link: https://doi.org/10.1016/..
 
?
12

Safety, Pharmacokinetic, and Functional Effects of the Nogo..:

Meininger, Vincent ; Pradat, Pierre-François ; Corse, Andrea...
PLoS ONE.  9 (2014)  5 - p. e97803 , 2014
Link: https://doi.org/10.1371/..
 
?
13

A Phase 2a, Randomized, Crossover Trial of Gabapentin Enaca..:

Harden, R. Norman ; Freeman, Roy ; Rainka, Michelle...
Pain Medicine.  14 (2013)  12 - p. 1918-1932 , 2013
Link: https://doi.org/10.1111/..
 
?
14

Dose finding by concentration-response versus dose-response..:

Berges, Alienor ; Chen, Chao
European Journal of Clinical Pharmacology.  69 (2013)  7 - p. 1391-1399 , 2013
Link: https://doi.org/10.1007/..
 
?
15

Non linear mixed effects analysis in PET PK-receptor occupa..:

Berges, Alienor ; Cunningham, Vincent J. ; Gunn, Roger N..
NeuroImage.  76 (2013)  - p. 155-166 , 2013
Link: https://doi.org/10.1016/..
 
1-15